Along this line, a remarkable tentative result for increasing the performance of the more novel approved TK inhibitor cabozantinib comes from recent preliminary data in mccRCC patients in which the addition of an HIF-2α inhibitor to cabozantinib improved clinical outcomes (2021 Genitourinary Cancer Symposium). This evidence concerns the gene EPAS1 and cancer.